1. New ghrelin agonist, HM01 alleviates constipation and L‐dopa‐delayed gastric emptying in 6‐hydroxydopamine rat model of Parkinson's disease
- Author
-
Karasawa, H, Pietra, C, Giuliano, C, Garcia‐Rubio, S, Xu, X, Yakabi, S, Taché, Y, and Wang, L
- Subjects
Neurosciences ,Parkinson's Disease ,Brain Disorders ,Neurodegenerative ,Digestive Diseases ,Prevention ,Nutrition ,Neurological ,Animals ,Antiparkinson Agents ,Brain ,Constipation ,Gastrointestinal Transit ,Ghrelin ,Immunohistochemistry ,Levodopa ,Male ,Oxidopamine ,Parkinsonian Disorders ,Rats ,Rats ,Sprague-Dawley ,6-hydroxydopamine ,constipation ,gastric emptying ,ghrelin agonist ,L-dopa ,Parkinson's disease ,Clinical Sciences ,Medical Physiology ,Gastroenterology & Hepatology - Abstract
BackgroundConstipation and L-dopa-induced gastric dysmotility are common gastrointestinal (GI) symptoms in Parkinson's disease (PD). We investigated the novel ghrelin agonist, HM01 influence on GI motor dysfunctions in 6-hydroxydopamine (6-OHDA) rats.MethodsHM01 pharmacological profiles were determined in vitro and in vivo in rats. We assessed changes in fecal output and water content, and gastric emptying (GE) in 6-OHDA rats treated with orogastric (og) HM01 and L-dopa/carbidopa (LD/CD, 20/2 mg/kg). Fos immunoreactivity (ir) cells in specific brain and lumbosacral spinal cord were quantified.Key resultsHM01 displayed a high binding affinity to ghrelin receptor (Ki: 1.42 ± 0.36 nM), 4.3 ± 1.0 h half-life and high brain/plasma ratio. 6-OHDA rats had reduced daily fecal output (22%) and water intake (23%) compared to controls. HM01 (3 and 10 mg/kg) similarly reversed the decreased 4-h fecal weight and water content in 6-OHDA rats. Basal GE was not modified in 6-OHDA rats, however, LD/CD (once or daily for 8 days) delayed GE in 6-OHDA and control rats that was prevented by HM01 (3 mg/kg acute or daily before LD/CD). HM01 increased Fos-ir cell number in the area postrema, arcuate nucleus, nucleus tractus solitarius, and lumbosacral intermediolateral column of 6-OHDA rats where 6-OHDA had a lowering effect compared to controls.Conclusions & inferences6-OHDA rats display constipation- and adipsia-like features of PD and L-dopa-inhibited GE. The new orally active ghrelin agonist, HM01 crosses the blood-brain barrier and alleviates these alterations suggesting a potential benefit for PD with GI disorders.
- Published
- 2014